PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis

PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis

Abstract Background The combinations of PD-1 inhibitors with paclitaxel/cisplatinum (PD-1 + TP) and fluoropyrimidine/cisplatinum (PD-1 + FP) both have been shown to improve overall survival (OS) and progression-free survival (PFS) in patients with previously untreated, advanced esophageal squamous c...

Full description

Bibliographic Details
Main Authors: Jia Zhao, Simeng Zhang, Xiaoyu Guo, Ce li, Bowen Yang, Xiujuan Qu, Shuo Wang
Format: Article
Language:English
Published: BMC 2023-12-01
Series:BMC Cancer
Subjects:
Esophageal squamous carcinoma
Paclitaxel
Cisplatin
PD-1 inhibitor
Meta analysis
Online Access:https://doi.org/10.1186/s12885-023-11715-3

Internet

https://doi.org/10.1186/s12885-023-11715-3

Similar Items